Topiroxostat is a selective xanthine oxidase inhibitor developed for treatment and management of hyperuricemia and gout. Xanthine oxidase, or xanthine oxidoreductase (XOR), regulates purine metabolism, and inhibition of the enzyme results in efficacious reduction of serum urate levels. Xanthine oxidase inhibitors are classified into two groups; purine analogs including [DB00437] and [DB05262], and non-purine agents which includes topiroxostat. While [DB00437] is considered a first-line therapy in treating hyperuricemic conditions, it is often associated with side effects and ineffective in reducing uric acid levels under recommended dosing regimens. It is grouped under the following drug class(es): Gout agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include uriadec, topiroxostatum and topiloric. Its PubChem CID is 5288320.
Topiroxostat
| CAS No | 577778-58-6 |
|---|---|
| Molecular Formula | C13H8N6 |
| Molecular Weight | 248.24 g/mol |
| Synonyms | 4-(5-pyridin-4-yl-1H-1,2,4-triazol-3-yl)pyridine-2-carbonitrile |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Topiroxostat is a selective xanthine oxidase inhibitor developed for treatment and management of hyperuricemia and gout. Xanthine oxidase, or xanthine oxidoreductase (XOR), regulates purine metabolism, and inhibition of the enzyme results in efficacious reduction of serum urate levels.
The listed CAS number is 577778-58-6.
The listed molecular formula is C13H8N6.
The listed molecular weight is 248.24 g/mol.
4-(5-pyridin-4-yl-1H-1,2,4-triazol-3-yl)pyridine-2-carbonitrile.
The source lists uriadec, topiroxostatum and topiloric.